Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 22, 2017
Pharmacy Choice - News - Front Page Healthcare News - August 22, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/22/17 - "Coplanar Wireless Energy Transfer" in Patent Application Approval Process (USPTO 20170216508)
By a News Reporter-Staff News Editor at Electronics Newsweekly A patent application by the inventors Zilbershlag, Michael; Naveh, Neri, filed on April 6, 2017, was made available online on August 10, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not been assigned t
8/22/17 - $889.3 mn for Global Contrast Injector Market by 2022
Zion Market Research has published a new report titled "Contrast Injector Market by Product (Injector Systems, Consumables, Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) - Global Indust...
8/22/17 - 2017 United States Insulin Pump Market Size Growth 2021 Forecast Research Report
ReportsMonitor.Com Adds United States Insulin Pump Market Insights, Opportunity, Analysis, Growth Potential & Forecast 2017 - 2022 to Its Database. United States Insulin Pump Market is likely to reach USD 4 Billion by the year end o...
8/22/17 - 3D Printing Medical Devices Market Worth 1.88 Billion USD by 2022
According to a new market research report " 3 D Printing Medical Devices Market by Component, Technology, Product Type- Global Forecast to 2022", published by MarketsandMarkets?, the global market is expected to reach USD 1.88 Billion by 2022 from USD 0.84 Billion in 2017, at CAGR of 17.5% from 2017 to 2022.. Browse 78 Market Data Tables and 31 F
8/22/17 - Values are relative when rooting for your political team
In his wary optimism after the U.S. Senate voted to proceed with debate on dismantling President Barack Obama s signature Affordable Care Act and replacing it with, well, something, Majority Leader Mitch McConnell of Kentucky said he and his supporters were not out here to spike the football.. And the opposing team is always the New Eng
8/22/17 - AEPP Announces Proposed Name Change to Oncolix, Inc.
AEPP, a Houston- based biotechnology company focused on gynecological cancers, today announced it intends to change its name to Oncolix, Inc. The new name is expected to be effective after the mailing of notice to its shareholders in September. AEPP recently acquired all of the outstanding securities of Oncolix, Inc. in a reverse merger completed
8/22/17 - Aisa Medical Tourism Market 2017 Key Players, Share, Trend, Applications, Segmentation and Forecast to 2022
Asia medical tourism market is anticipated to cross US$ 14 Billion mark by 2022. Asia continues to be the top medical destination in medical travel. In countries such as Singapore and Thailand, government agencies have been set up to help market their expertise globally. Thailand accounts for maximum share of the Asia medical tourism market, being
8/22/17 - ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada [T-break Tech (Middle East)]
The FDA has today transferred the US product licences for the SLIT-tablet portfolio to ALK allowing the company to give full speed on the US activities. ALK plans to expand pivotal Phase III clinical trial on allergic asthma to include US patients based on discussions with the FDA. Full-year financial guidance for operating profit has been revised
8/22/17 - Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
Release date- 21082017- DUBLIN- Alkermes plc today announced the initiation of its rolling submission of a New Drug Application to the U.S. Food and Drug Administration, seeking marketing approval of ALKS 5461, a once daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder.
8/22/17 - Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer
The Alliance Foundation Trials, LLC, in conjunction with Pfizer and six international cancer research groups, today announced the launch of PATINA a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/ 6 inhibitor palbociclib. The PATINA trial offers an exciting opportunity for a new global collaborative initiative
8/22/17 - ALP Nutrition Products Now Available on Multiple Online Retail Sites [Algeria Press Service]
-ALP Nutrition, a company based in Germany that creates a variety of high-quality liquid food supplements, is pushing its marketing strategy by making its products available on a wide range of popular sites. Its products are available both on major retail platforms and specialty nutritional supplement sites like,,...
Release date- 21082017- GAITHERSBURG, Md.- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Company's intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimm
8/22/17 - Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial [Syrian Arab News Agency]
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, the Companys intranasally administered recombinant flu vaccine. Sybil Tasker, Chief Medical Officer at Altimmune. Current vaccines leave significant room
8/22/17 - AMA Offers Comments to CMS on Its 2018 Medicare Reform Proposal
The American Medical Association issued the following news release:. The American Medical Association submitted comprehensive comments today to the Centers for Medicare& Medicaid Services and outlined recommended changes to the proposed rule on Medicare payment and delivery reform, as created by the Medicare Access and CHIP Reauthorization Act.
8/22/17 - AMCP Submits Comments to CMS on the CY 2018 Updates to the Quality Payment Program
The Academy of Managed Care Pharmacy issued the text of the following letter:. Centers for Medicare& Medicaid Services. The Academy of Managed Care Pharmacy thanks the Centers for Medicare and Medicaid Services for the opportunity to comment on the Proposed Rule, Medicare Program; CY 2018 Updates to the Quality Payment Program.
8/22/17 - AMGA: Proposed MACRA Rule Needs Significant Changes to Support a Value-Based Medicare Program
The American Medical Group Association issued the following news:. AMGA today calls for the Centers for Medicare& Medicaid Services to revise its proposed rule for the Quality Payment Program. AMGA is particularly concerned about CMS' proposal to increase the low-volume threshold and exclude Medicare Advantage from the advanced Alternative Payment
8/22/17 - Analysis on Implantable Drug Delivery Devices Market Report Upto 2023
The new research report on Implantable Drug Delivery Devices Market offered by provides Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016-2023. The global implantable drug delivery devices market research r...
8/22/17 - Antimicrobial Coatings for Medical Devices Welcome Gradual Boost from Technology Advancements and Consumer Awareness of Benefits
The Asia-Pacific and the Middle East markets will be hotspots, while Europe will witness sluggish growth due to rising cost pressures and a maturing market. Global Antimicrobial Coating Materials Market for Medical Devices, Forecast to 2021, analysis from Frost& Sullivan's Visionary Science Growth Partnership Service program, finds that the global.
8/22/17 - Antimicrobial Coatings Market to Gain From Increasing Need of Hygiene in Various Industries From 2014 to 2025: Million Insights
The global antimicrobial coating market was worth USD 2.44 billion in 2015. Indian pharmaceutical companies are driving into antimicrobial market to be in line with the regulatory standards. The effect of micro-organisms on people improves health concerns owing to boost the market over the forecast period.
8/22/17 - Apple Rehab Watch Hill Elevates Treatment for Wound Care and Parkinson's
Nurses at Apple Rehab Watch Hill, a nursing and rehabilitation facility nestled on five acres at picturesque Babcock Cove, recently received training and certification in Closed Pulse Irrigation? for wound care. This qualifies Apple Rehab Watch Hill, which has a prestigious five-star rating from the Centers for Medicare and Medicaid Services, to
8/22/17 - Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress [T-break Tech (Middle East)]
-Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today announced that an interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of...
8/22/17 - Astellas Pharma Inc. - First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy
Release date- 21082017- TOKYO- Astellas Pharma Inc. announced today that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the fourth Phase 3 trial underway in the gilteritinib clinical development program. 'We know that FLT3+ AML patients face potentially worse outcomes than those with other mutations, and whi
8/22/17 - AstraZeneca plc. (ADR)(NYSE:AZN) Invests $29.5 Million In Ethris For mRNA-based Therapies Development
AstraZeneca plc. (ADR)(NYSE:AZN) has inked a strategic collaboration agreement with Ethris for the development of mRNA-based respiratory disease therapies. The five-year strategic collaboration seeks to leverage Ethris proprietary Stabilized Non-Immunogenic mRNA technology. AstraZeneca-Ethris Collaboration Under the terms of the agreement, Ethris i
8/22/17 - Aurobindo Pharma gets USFDA nod for anti-HIV drug [Arab News (Saudi Arabia)]
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. In a BSE filing, Aurobindo Pharma said it has received "tentative approval from the US Food and Drug Administration under the US President`s Emergency Plan For AIDS
8/22/17 - B. Braun Launches New Dialyzer
B. Braun Medical issued the following news release:. B. Braun Medical Inc. today announced that the U.S. Food and Drug Administration has cleared its hemodialyzer, Diacap (R) Pro. "The newly developed fibers in Diacap Pro are designed to improve dialysis dose," said Samuel Amory, Vice President at B. Braun Medical.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement